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1. Introduction
Arboviruses (arthropod-borne viruses) are a group of pathogens that are transmitted by
hematophagous arthropods, mainly mosquitoes and ticks, between susceptible vertebrates
[1]; many of them are also characterized by their movement through arthropod communi‐
ties: vertical (or transovarial) [2] and venereal transmission [3]. Thus far, more than 500 ar‐
boviruses have been identified worldwide, particularly in tropical and subtropical areas
[4-6]. Of these, some 80 species can cause human diseases with a broad spectrum of symp‐
toms, including encephalitis, fever, and hemorrhaging [7]. Most arboviruses are classified
into three families (the Togaviridae, Flaviviridae, and Bunyaviridae) in the current viral clas‐
sification system. Minor groups of arboviruses include those belonging to the Rhabdoviri‐
dae (vesicular stomatitis Indian and bovine ephemeral fever viruses), Reoviridae (blue-
tongue virus and Colorado tick fever), and Asfarviridae (African swine fever virus; ASFV);
all of which have trivial or no roles in causing human diseases.
Viruses belonging to the Togaviridae are enveloped and spherical with a size of 65~70 nm in
diameter; they contain an icosahedral nucleocapsid within which is included single-strand‐
ed positive-sense RNA [8]. Viral RNA serves as both the genome and viral messenger
(m)RNA. The entire genome encodes a non-structural polyprotein which is processed by
host and viral proteases, while a structural polyprotein is expressed by subgenomic mRNA
[9]. The genus Alphavirus in the family Togaviridae includes 29 virus species, all of which
are transmitted by mosquitoes [10]. The Flaviviridae is composed of viruses that also con‐
tain single-stranded positive-sense RNA; however, their virions are smaller in size than Al‐
phaviruses, usually 45~50 nm in diameter [11]. The genus Flavivirus contains about 70
members; a number of them are infectious to humans, e.g., dengue virus and West Nile
(WN) virus. Flaviviral RNA possesses a single open reading frame, encoding a polyprotein,
which is then processed to three structural proteins (C, M, and E) and seven non-structural
proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) by host and viral proteases [11].
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The Bunyaviridae is one of the largest groupings of animal viruses, containing more than
300 viruses [12]. Except for the genus Hantavirus, all of them are transmitted by arthropods
[12]. Viral particles are spherical with a size >100 nm in diameter, and are composed of four
structural proteins encoded on its tripartite single-stranded negative-sense RNA genome
consisting of the L, M, and S segments [13].
Various arboviruses belonging to those three major families can specifically cause encephali‐
tis. Of these, Eastern equine encephalitis (EEE) virus, Western equine encephalitis (WEE) vi‐
rus, and Venezuelan encephalitis (VEE) virus belong to the Togaviridae [14], Japanese
encephalitis (JE) virus, St. Louis encephalitis (SLE) virus, WN virus, and tick-borne encepha‐
litis (TBE) virus are from the Flaviviridae [15, 16], while California encephalitis (CE) virus
and La Crosse (LAC) virus are members of the Bunyaviridae [7]. Recently, increasing evi‐
dence has shown that certain arboviruses such as dengue (DENV) and chikungunya viruses
(CHIKV) may occasionally cause encephalitis in addition to their conventional symp‐
toms,which usually involves headaches, muscle and joint pain, and rashes [17-19].
2. Epidemiology of encephalitic arboviruses
Arboviruses are usually transmitted through bites of blood-feeding arthropods (primarily
mosquitoes and ticks) in two major cycles (Figure 1). The man-arthropod-man cycle is char‐
acteristic of dengue virus, while EEE, WEE, WN, JE, and CE viruses are transmitted by an
alternative cycle involving non-human mammals and birds [10]. For the infections by arbo‐
viruses that cause encephalitis, humans or horses become an incidental or dead-end host,
while animals such as birds and pigs serve as reservoirs or amplifying hosts [20].
Togaviridae. Viruses causing EEE, WEE, and VEE are all members of the Alphavirus genus in
the family Togaviridae [21]. In fact, they are the only viruses in this group that commonly
cause encephalitis and are restricted to the Americas. There are other Alphaviruses also with
limited distributions, such as CHIKV (Asia and Africa), O'nyong-nyong virus (Africa), Sind‐
bis virus (Africa, Europe, and Asia), Mayaro virus (South America), and Ross River virus
(Australia), however these are expected to eventually become distributed worldwide [22].
Epidemiologically, all Togaviridae are similar in that these viruses have wild avian hosts,
are transmitted from birds to mammals by mosquitoes, and may cause encephalitis in hors‐
es and humans [22].
Flaviviridae. At least 7 arboviruses including TBE, Kyasanur Forest disease (KFD), JE, Mur‐
ray Valley encephalitis (MVE), SLE, Rocio, and WN viruses are reported to be associated
with causing encephalitic symptoms [23]. Some of these are described below.
The TBE virus is a member of the family Flaviviridae, which is geographically distributed
worldwide, usually in rural areas at temperate latitudes, including all over Europe and the
Scandinavia, the former Soviet Union, and East Asia [24]. Incidences of human cases mark‐
edly increased in the early 1990s, mostly in Europe [25]. It was reported that the TBE inci‐
dence was 8690 cases during 1965~1992, while 8674 cases were documented in a smaller
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window of time between 1993 and 2006 in the Czech Republic, indicating a steep rise in this
region [25]. Rodents are the primary reservoir hosts of this virus, which is transmitted by the
bites of hard ticks (Ixodes) in nature [24].
Figure 1. Transmission cycles of arboviruses in nature. Two major cycles cover the transmission of most arboviruses,
one is mam-to-man and the other usually involves non-human mammals and birds.
The JE virus is mainly amplified in pigs and birds and are transmitted by Culex mosquitoes
(primarily Cx. tritaeneorhunchus) between vertebrates [26]; it causes a significant number of
human encephalitis cases in most areas of Asia, especially eastern, southern, and southeast‐
ern Asia, as well as the South Pacific regions [27]. It recently expanded to the Torres Strait of
northern Australia in 1999, and has now become endemic in Australia [28, 29]. JE virus is
estimated to cause about 30,000~50,000 cases each year worldwide [15, 30]; of which,
10,000~15,000 may be fatal [31].
WN virus was first isolated from a febrile patient in the West Nile region of Uganda in 1937
[32]. It has caused epidemics in Africa, Europe, the Middle East, Asia, and, more recently, in
North America [33]. Since the emergence of WN virus in the United States in 1999, it has
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spread all over North America and caused more than 20,000 humans to be ill and 770 deaths
(http://www.cdc.gov/ncidod/dvbid/westnile/surv and control.htm). Neuroinvasive disease
due to WN virus infection can occur, 2946 and 2866 cases were reported in 2002 and 2003,
respectively [34].
The SLE virus is a close relative to WN virus, and actually is a member of the Japanese ence‐
phalitis serocomplex [35]. Predominantly, SLE virus is naturally maintained in a transmis‐
sion cycle between ornithophilic mosquitoes and birds, but occasionally these arthropods
feed on mammalian blood, causing encephalitis in humans [36]. Nearly 5000 human infec‐
tions were reported between 1964 and 2005, making it the major cause of epidemic encepha‐
litis in association with flaviviral infections before the introduction of WN virus into the
United States (http://www.cdc.gov/ncidod/dvbid/arbor/pdf/SLEDOC07132006.pdf).
Buynaviridae. In this family, viruses involving symptoms of encephalitis include Rift Valley
fever (RVF), LAC, CE, and Jamestown Canyon [37]; all are mosquito-borne. RVF virus most‐
ly occurs in Africa and the Middle East, while the other three, which are classified in the
California serogroup, are restrictedly distributed in North America [37]. Of these, the LAC
virus causes the most human disease, with dozens to hundreds of hospitalized cases report‐
ed each year in the United States [38]; unlike EEE, California serogroup including LAC is
not dependent on avian hosts for natural transmission. Rodents usually serve as its major
vertebrate host [37].
3. Mechanism of central nervous system (CNS) infection by arboviruses
Despite many years of intensive efforts and investigations on the pathways leading to infec‐
tions of the CNS by arboviral families after the bite of an arthropod carrying an infectious
agent, the exact mechanism remains to be further delineated. There are multiple routes that
can be considered, depending on the characteristics of the virus. Some advocate the mecha‐
nism of direct viral spread from the periphery to the CNS [39], particularly for arboviruses
involved in brain infections. It is thought that these viruses are amplified in dermal tissues
and then in lymph nodes via migration of dendritic (Langerhans) cells before invading the
CNS [40, 41]. However, the mechanism allowing for these viruses to perform the last step, to
enter and invade the CNS, is less clear. The MVE, SLE, and JE viruses were speculated to
enter the CNS via the olfactory pathway [42], while transcytosis across cerebral capillary en‐
dothelial cells was reported in JE [43]. In addition, virion-budding on the parenchymal cells
after replication at the blood-brain barrier may also occur [44]. In experimental models,
many infections by encephalitic arboviruses are diffusely spread throughout the brain [45,
46]. Furthermore, the absence of viral antigens in the choroid plexus or ependyma indicate
that these viruses were not actively targeted to and replicated in this tissue but rather en‐
tered the CNS via a hematogenous route [47] (Figure 2), especially in patients with severe
viremia [48].
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Figure 2. Hypothetic routes for arboviruses to infect the brain tissue hematogenously. (A) Infection of endothelial cells
before the virion enters the brain tissue. (B) Virions enter the brain tissue through disrupted BBB. (C) Infected white
blood cells enter the brain tissue by passing through the disrupted BBB.
In a study on JE, extensive infection of neurons resulting in cellular defects was shown in
the cerebrum and cerebellum [49]. The cerebral and cerebellar capillary endothelial cells are
responsible for maintaining the integrity of the blood-brain barrier (BBB) [50]. In both ani‐
mals and humans, the BBB generally prevents viral invasion into the CNS [51], unless it has
been disrupted, resulting in increased permeability and inflammatory cell infiltration [52,
53]. Disruptions in the BBB actually allows for peripheral blood mononuclear cells (PBMCs)
to migrate from the circulation into brain tissues [54, 55].
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Under normal circumstances, lymphocytes constantly enter the CNS, but in small numbers
[56]. However their presence in the CNS may increase in response to viral infections [57]. In
fact, infected PBMCs can be isolated in brains from mice inoculated with JE virus as early as
3 days post-infection [58]. Moreover, leukocytes were observed moving between endothelial
cells of capillaries at sites in the BBB where tight junctions had been dissociated [49]. This
suggests that at least some inflammatory leukocytes that had become infected in the periph‐
ery move along in the blood current and migrate to the CNS tissues [58, 59]. Furthermore,
infection and resultant apoptosis of astrocytes, which serve as a protective component of the
BBB and can defend against penetrated virions or virus-infected leukocytes, are frequently
seen in the brain. This probably results in severe impairment of the BBB, facilitating the pas‐
sage of more virus-infected PBMCs, using a “Trojan horse” strategy.
4. Pathogenesis of arboviral infections
Arboviral diseases start with a bite from an arthropod creature carrying infectious virus.
The pathogen may be considered an innocent bystander or an unnecessary byproduct from
an infected vertebrate host. The arthropod imbibes this blood for its own purposes, to facili‐
tate ovulation, and takes up the accompanying virus in the meal. The presence of pathogen
is not a critical event in the life cycle of the insect and may or may not cause it harm. The
persistence of disease is none of these creatures’ fault, since survival is the game plan for all
organisms on earth. In many instances, arboviruses are capable of surviving inside the com‐
ing host without inducing any visible adverse effects. Given the opportunity, the pathogens
will reentry and challenge a new host. If the host is capable of implementing a “survival
strategy” in response to the viral infection, the host will be fine. Occasionally, these crea‐
tures may enter a host, such as human beings, in which the environment may not be as
friendly as others, and a hostile survival race is engaged. The race tactics instigated by both
sides are normally controllable and do not result in overt disease. But in some cases, the reg‐
ulatory programs in the host do not coordinate well with each other or could also be distur‐
bed and/or handcuffed by substances released from the pathogens. This can result in
dysfunctional operational systems that are harmful to the host, leading to detrimental out‐
comes, including death. As a whole, the occurrence of the severe consequences is very rare.
For instance, with JEV infection, the overall global incidence of cases annually is at 1.8 per
100,000 people [60].
Timing is critical in the diagnosis of acute arboviral encephalitis. The progression and varia‐
tion in clinical manifestations among infected subjects may differ, depending on the individ‐
ual’s age and geographical habitat, the arthropod’s feeding behavior, genetic differences in
the viral strain, and the immune status of the affected patients. One of the common clinical
features in arboviral infections is viremia. However, the duration and level of this viremia in
humans is significantly different with each and every family of viruses. In a commensal ar‐
boviral-host relationship, one may expect high levels of viremia to cause too much patho‐
genesis in the host but too low levels to not facilitate transmission. One may expect a
consistent middle range in viremia to be obtained. Extreme variation in or high titers of vi‐
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rus in the blood may be a sign that humans are an accidental or dead-end host to most arbo‐
viruses. Identifying the cellular sources responsible for viremia will likely help us uncover
the underlying mechanisms leading to arboviral encephalitis and aid in the development of
vaccines and anti-viral drugs. Because of this, finding the permissive cell lineages account‐
ing for circulating virus in infected patients has been the central focus for several decades. In
spite of these efforts, the answer remains elusive.
Figure 3. The possible route of the virus in vertebrates from peripheral tissues to the brain. Arboviral infections start
with the bite of insects carrying an infectious virus. The exact location where the virus is deposited remains poorly un‐
derstood. There are multiple ways a virus may spread and circulate before reaching to the brain. Please refer to the
text for more details.
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Arboviral infections are introduced into the hosts during the blood meals of arthropods car‐
rying infectious virus. The first obstacle that the arthropod encounters is the physical barrier
of the skin, which is composed of several layers of keratinocytes interspersed with a net‐
work of capillaries (Figure 3). There are two possible routes that the virus may use as a res‐
ervoir to amplify the progeny after its deposition by the mosquito. One passage way may be
released into the blood pools of lacerated capillaries. In this situation, it is generally as‐
sumed that the initial target cell supporting the viral replication is Langerhans dendritic
cells of the skin (Figure 3, route 1) [61]. The infected Langerhans dendritic cells migrate to
draining lymph nodes where a brief viral replication may occur and the virus is considered
to enter the blood stream through the lymphatic and thoracic ducts [61]. The virus may en‐
ter the bone marrow [62] or liver [63] where a secondary amplification may occur or directly
disseminate to the brain inducing inflammation.
An alternate route would be direct deposition of the viruses into the blood stream (Figure 3,
route 2), or so-called capillary feeding, during the engorgement of the arthropod. Results
from RVFV suggest that the liver seems to be an early and dominant target of the virus [63].
The damage to the hepatocytes of the RVFV-infected liver is likely a result of apoptosis [63].
The evidence suggests that this virus may get deposit directly into the capillary and take a
ride through the circulation to the liver compartment where permissive cells, likely hepato‐
cytes, provide RVFV a means to produce progeny (Figure 3). In addition, studies investigat‐
ing mosquito imbibing behavior with Aedes aegypti revealed that the mosquito’s proboscis is
flexible and predominantly obtains blood directly from the capillary and only occasionally
from the blood pools formed in the tissues by the leakage from previously lacerated capilla‐
ries [64]. These results were later confirmed with the mouse's ear and human beings imple‐
menting the same experimental designs [65, 66]. In this route (Figure 3, route 2), the virus
may gain access directly to the bone marrow where a brief viral replication can occur, ex‐
travasates into the circulation, disseminates to other parts of the body, and penetrates the
brain via mechanisms discussed in Figure 2.
However, determining the first cells infected by the viruses subsequent to the bite remains a
challenging event to investigators. The scenario via route 1 (Figure 3) is complicated by a
number of issues. Keratinocytes on the outermost epidermal layer of the skin are endowed
with toll-like-receptors (TLR) [67] and may be considered a component of the primary in‐
nate immune system. Langerhans cells mainly reside in the thin layer of the epidermis,
which does not contain capillaries, while the dendritic cells are predominantly in the thicker
dermis layer, which is filled with capillaries. Route 1 has been extensively investigated with
diseases derived from mosquito-borne viruses. This pathway could be the true route for
those viruses belonging to the human-is-dead-end-host group, since the virus titers from
these cells are too low to permit transmission to new mosquitoes. In contrast, if human be‐
ings are the host for the virus, such as dengue virus, then the assumption that this virus
takes this route should be reconsidered. Experiments have revealed that only a very short
window period is available for dengue virus to be transmitted, during the high viremic
stage, usually within 3-5 days after the onset of the clinical fever. Thus, if the mosquitoes
imbibe the blood meal during this stage, the virus will spillover and infect the local Langer‐
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hans dendritic cells and the cycle of illness will resume. If this is the case, then we would
observe a sinusoidal wave-like pattern for viremia in infected dengue patients. But in reali‐
ty, this is not the case. Thus, this evidence indicates that an alternate route could exist, such
as direct deposition of virus into the blood stream. Interestingly, it has been suggested that
during imbibing, approximately 50% of the fascicle penetrates into the skin [68], suggesting
that the location of the blood drawn by the vector is from the capillary-rich dermis layer,
implicating that pathogens may be directly injected into the blood.
One of the puzzling issues is what cellular constituents are the protective components in
asymptomatic cases. Interestingly, apoptotic keratinocytes and dendritic cells are observed
in human skin explants when dengue virus is directly injected into the epidermis with a fine
needle [69]. Considering the fact that a majority of dengue virus infections are asymptomat‐
ic, this evidence suggests that the role of dendritic cells at the site of fascicle penetration is to
eliminate or temporarily contain the intruders and thereby prevent or reduce the dissemina‐
tion of dengue virus. However, the role of keratinocytes and dendritic cells in clearance of
dengue virus remains to be further investigated.
Although most persons bitten by an infected mosquito will experience no symptoms or will
have a very mild presentation of the disease, approximately 1 to 2 percent will develop a
recognizable illness. The clinical symptoms for the initial phase of arboviral encephalitis are
very similar and similarly variable from person-to-person for all the virus families. Some in‐
dividuals may have mild symptoms, such as a fever and headache, while others may have a
more severe presentation. In this case, symptoms may include a rapid onset of severe head‐
ache, high fever, muscle aches, stiffness in the back of the neck, and problems with muscle
coordination, disorientation, photophobia, convulsions and coma. The illness will usually
occur five to 15 days after the bite of an infected mosquito or tick. However, the symptoms
may resemble other common febrile illnesses. Thus, in order to diagnose correctly and de‐
termine the proper treatment in a timely manner, it is important to seek professional help
immediately or as soon as clinical signs appear.
In order for an affected subject to have a risk for neurological disorder, the virus entering
the human host has to possess two major criteria: neuroinvasiveness and neruovirulence.
The term “neuroinvasiveness” means that the virus is capable of passing or crossing
through the BBB, a structure that separates the immune privileged compartment of the brain
from the peripheral system. The term “neruovirulence” refers to the capacity of viral replica‐
tion in the CNS tissues. There are several mechanisms involved on the induction of neuroin‐
vasion. The virus can either replicate and induced damage of the nearby endothelial cells
[70] in the cerebral capillary or in striated muscle [71] surrounding the BBB. Alternatively,
virus may enter the CNS by endocytosis via the olfactory bulb or the choroid plexus, for ex‐
ample, JEV [43], CHIKV [72] and VEEV [73]. In addition, high viremia is a major feature of
only some of the arboviral infections, thus some viruses can cross the BBB via the vascular
route by passive transfer carried by infected leukocytes [74]. Spreading virus to the CNS
through the trigeminal nerve after local amplification of the virus has been proposed as well
[73]. The neurological symptoms induced by some of these arboviruses, which are able to
increase the permeability of vasculature and spillover into the CNS, are capable of disrupt‐
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ing cognitive biological processes. In order to differentiate the evasion strategies employed,
animal models are required. Currently, there are only a limited number of animal models
available for a few arboviruses; JEV [59], EEEV [75], LACV [71], WNV [76] and CHIKV [72].
However, the cardinal features of human clinical encephalitis induced by these arboviruses
are hardly reproduced in these models. Therefore, what the exact mechanisms by which ar‐
boviruses cross the BBB remains poorly understood, as well as the precise mechanisms by
which circulating peripheral pathogens induce the inflammation of the brain remain largely
unknown.
Nevertheless, the best systems available that have been used to characterize the biological
properties of arboviruses in animal models are the WNV [76, 77], LACV [71], EEEV [75], and
CHIKV [72, 78]. Results revealed that viral strain variations, in addition to the host age and
immune conditions, contribute a significantly to neuroinvasiveness and neurovirulence. In‐
fection of the mice intradermally or subcutaneously leads to the robust replication of WNV,
LACV, and CHIKV in the brain, particularly in newborn mice. But the mechanisms contri‐
buting to neurotropism of other viruses are less clear since suitable models are not available.
When viruses enter the CNS, a variety of cells are permissive for infection [46, 79]; some
cells may be more susceptible than others, and the viruses may have their differential prefer‐
ences [74, 75, 78, 80]. Regardless, the net consequence is the activation and/or damage to res‐
idential cells. This results in the recruitment of defense cells with immune system functions
to the damaged site. An inflammatory response occurs due to the presence of an overpro‐
duction of multiple functional cytokines from the infiltrating cells [81-83]. The nature of the
privileged environment of the brain bestows it with characteristics that make restoration to
the default normal status far more complicated than other parts of the body. The most sali‐
ent feature of the brain is that a large proportion of the cells are terminally differentiated.
These cells are very difficult to renew and replace. Therefore, affected encephalitic patients
suffer long-term neurological impairment as a result from the infection [18, 28]. These symp‐
toms include short-term or long-term memory loss, seizures, and impaired judgment [28, 84,
85]. A neurological exam is performed to evaluate the mental status, detect neurological
problems, such as motor dysfunction and seizures, and help determine which area of the
brain is affected [18].
The causes of the dysfunctional circuitry in neurons are likely different among the arbovi‐
ruses. Some viruses have the capacity of direct engagement with neurons by infection, while
others may induce cell death or apoptosis in nearby cells, which shed releasates, likely trig‐
gering a cascade of events that damages the neuronal tissue [81, 82]. This may be why some
viruses can be recovered from the CNS easier than others in autopsy specimens. For those
viruses capable of infecting small animals, results also suggest the observed scenarios. In
contrast, for the viruses with limited capacity to replicate in animal models, the actual caus‐
es of neurological symptoms are less clear.
The initial symptoms of the arbovirus infections that induced encephalitis are very similar,
especially for those mild cases of encephalitis, which makes the correct diagnosis a challenge
to physicians. In order for accurate diagnosis, in addition to the routine examination on the
physical performance, specific tests are required, such as electroencephalogram, brain mag‐
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netic resonance imaging (MRI) and X-ray computed tomography (CT). These tests allow for
a scan of the head to detect abnormalities, such as swelling (edema) and bleeding (hemor‐
rhage) [86]. These sophisticated instruments are likely available in very advanced clinics and
may not be very convenient or available for the majority of patients affected by arboviral en‐
cephalitis. Thus, alternate diagnostic methods are applied. These are biological approaches,
which include virus isolation from cerebrospinal fluid, blood, and biopsy specimens, detec‐
tion of viral genetic and/or antigenic materials, and specific antibodies to the virus. Howev‐
er, there are pros and cons for each of these diagnostic assays. Sensitivity and specificity,
and antibody cross-reactivity are always a concern.
5. Treatment of arboviral infections
Currently used drugs to treat arboviral encephalitis. There is no cure for arboviral encephalitis
and treatment is generally supportive, with maintenance of respiratory and circulatory sys‐
tems while the infection runs its course. The purpose of the palliative care is to reduce the
malfunctioning of critical organs and to relieve symptoms, while the body fights the infec‐
tion. The priority of the treatment is to ensure the alleviation of pain, as well as to mitigate
the swelling in the brain, reduce the fever and prevent dehydration and other chemical im‐
balances by administration of intravenous fluids. As a whole, the treatment for arboviral en‐
cephalitis depends on the cause. Some clinical cases of arboviral encephalitis can be
mitigated successfully if medication is started as soon as possible. A number of therapeutic
drugs specific to arboviral infections are under investigation for their potential antiviral and
neuroprotective effects: minocycline and curcumin for JEV and other arboviruses [87-89],
ribavirin for LACV [90], interferon (Omr-IgG-aM) and humanized monoclonal antibody
(Mab E16) as a potential candidate for WNV treatment [61, 91, 92]. However, currently there
is limited information available on the effectiveness of these therapeutic modalities in the
clinical setting. Additionally, there are a number of reliable medicines that are commonly
prescribed to treat the symptoms mentioned above; administration of benzodiazepines (e.g.,
lorazepam [Ativan®) to prevent seizure, diuretics drugs (e.g., furosemide or mannitol) to re‐
duce brain swelling, sedatives to relieve irritability, antibiotics to prevent secondary infec‐
tions, and acetaminophen to control fever and headache. For those patients whose brain
functions may be severely affected, interventions like physical therapy and speech therapy
may be needed after the illness is controlled.
6. New drug development
The life cycle of arboviruses in vivo is not well understood, even though a great amount of
detail on the comprehensive biology of these viruses in vitro has been intensively investigat‐
ed and uncovered. As aforementioned, the genetic material for a majority of the arbovriuses
is positive-sense single-stranded RNA, which can function as mRNA and be infectious by
itself. It has been proposed that this genomic viral RNA can become encapsulated within the
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biological material from the host cell to form an infectious vesicle.These particles may fuse
with other biologically functional identities, potentially leading to the initiation of new in‐
fections, which can result in the formation of completed and perfect virions. Interference
with the processes and network signaling involving classical virion formation has been a
common target for drug development. However, in reality, the perfect virion in vivo has not
been visualized, suggesting an alternate form of virion may exist in vivo. Consequently, the
real structures needed to design the intervention remains elusive. Furthermore, diseases in‐
duced by arboviruses are acute illnesses where timing is critical. Infected individuals nor‐
mally delay in seeking professional help, resulting in the subjects arriving at the hospital in
a far worsen condition. Thus, the availability of intervention drugs, the timing of the admin‐
istration and the effect of the drugs on the arboviral infections remain critical issues.
7. Prognosis
Prognosis depends on the particular type of arbovirus causing disease, and on the age and
prior health status of the patient. The prognosis is worse in very young patients, elderly pa‐
tients, and patients with compromised immune systems. LAC encephalitis most often oc‐
curs in children, while WNV and SLV encephalitis usually occur in persons older than 50
years of age [20]. Encephalitis caused by EEV and JEV carries a high risk for serious neuro‐
logical damage and death. Death rates range all the way up to 20% for arboviral encephali‐
tis, and the rates of lifelong effects due to brain damage can reach 60% for some types of
arboviruses.
8. Vaccine prevention for arboviral infections
Infection with an arbovirus provides immunity to that specific virus, but not to other arbovi‐
ruses, suggesting that arboviral infection is a vaccine preventable disease. Thus, the devel‐
opment of new, more effective vaccines and the appropriate animal models in which to test
them are paramount. Although for many important arboviruses, there are currently no ap‐
proved vaccines available for human use, while for some, safe and effective vaccines have
been used for decades. For instance, a clinical approved inactivated vaccine against TBEV
has been used in Russia, Germany, Austria, and China [93].
JEV is one of the few arboviruses for which a vaccine is available. The JEV vaccine made
from infected mouse brain can achieve efficacies of at least 80% [94]. But because of the cost
and safety concerns, development of a better JEV vaccine has been an ongoing project. For
example, the development of a live-attenuated virus vaccine (SA14-14-2, for use in China
and a part of Asia) and more recently, in March 2009, the FDA approved a new, inactivated
cell-culture-derived JEV vaccine (IXIARO) for use in adult travelers over the age of 17
[95-98]. In addition, a live-attenuated yellow fever–Japanese encephalitis chimeric vaccine
(IMOJEV™) was recently licensed in Australia and is under review in Thailand [98].
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As for WNV, an approved and efficacious vaccine for humans is not available, even though
equine WNV vaccines are in use [99]. However, it is anticipated that a WNV vaccine for hu‐
man use will be available within a couple of years. In addition, inactivated TBEV vaccine is
currently available in Europe [100].
For others, such as the Alphaviruses, human vaccines are available only as Investigational
New Drugs, and thus are not in widespread use.The rest of the arboviral vaccines are cur‐
rently undergoing clinical phase III trials, and are anticipated to be available for public us‐
age within 5 years if everything goes as planned. While some of these vaccines have
currently only received approval for animal usage, newer versions for human use are in the
process of being evaluated or developed.
New challenges in vaccine development have been met with new technologies in vaccine re‐
search. Many of the newer vaccines are now being developed by recombinant DNA technol‐
ogy [100]. For example, chimeric virus vaccines have been developed using infectious clone
technology for many arboviruses including, WNV, JEV, and TBEV. Other successful ap‐
proaches have involved the use of naked DNA encoding and subsequently expressing the
desired protective epitopes. Naked DNA vaccines have been used for TBEV and JEV and are
currently under development for use against WNV. The development of less expensive,
more authentic animal models to evaluate new vaccines against arboviral diseases will be‐
come increasingly important as these new approaches in vaccine research are realized.
However, technical issues do exist in the nature of these viruses. One of the unique biologi‐
cal features in a majority of arboviruses is the constitution of the genetic material. The posi‐
tive-sense single-stranded RNA genome can function as mRNA, which is capable of
producing an infectious virus if the RNA is inside a biologically functional identity. To add
the second layer of difficulty in vaccine development, arboviruses may have multiple life cy‐
cles, since the physical morphology of these virions may be a mosaic form in vivo [62]. These
features may be one of the reasons why developing a vaccine against arboviruses is such a
difficult task. Despite the potential dilemma, there are some successes; though continued
improvement in developing arboviral vaccines that are capable of preventing encephalitis is
an urgently needed and challenging task.
Other foreseeable methods for areas where arboviral encephalitis is prevalent include insec‐
ticide spraying, which may be used to control outbreaks. Wearing insect repellent and
avoiding outdoor activities when mosquitoes are active may also be helpful.
9. Conclusion and perspective
Arboviral encephalitis is a very significant human disease and is caused by a large group of
viruses distributed across multiple virus families. The virus is introduced to human beings
by hematophagous arthropods, mainly mosquitoes and ticks. With a wide spectrum of clini‐
cal manifestations, the diseases are very difficult to diagnose and treat. Although arboviral
infections are vaccine preventable and treatable diseases, only a couple of anti-viral thera‐
Arboviral Encephalitis
http://dx.doi.org/10.5772/52327
85
peutic drugs and vaccines are available. However, several new drugs are undergoing clini‐
cal trials and some will likely become available within 5 years. Animal models that can
capture the cardinal features of disease seen in their human counterparts will be a very criti‐
cal technological advance. Using adequate animal models can pave the way for understand‐
ing and uncovering the paramount host and viral factors responsible for breaking down the
BBB and leading to the penetration of the virus into the CNS, as well as serving as a good
platform to test for effective and preventive modalities.
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